What did @titatots actually say?
On day one of tirzepatide, the creator reported feeling significantly better than they did on semaglutide. They described semaglutide as making them "so sick, so beyond nauseous" and noted only mild early-morning nausea with tirzepatide that resolved after taking ondansetron (Zofran) and going back to sleep. This is a personal tolerability comparison, not a clinical claim, but it carries real weight at 16K views.
To be clear: the creator is sharing an anecdote. Day one on any GLP-1 or dual GIP/GLP-1 agonist is not a reliable indicator of how the full course will feel. Nausea on these medications tends to peak during dose escalation, not at the starting dose. Still, the underlying question, whether tirzepatide is easier on the stomach than semaglutide, is actually worth examining.
Does the science back this up?
Somewhat, yes, though the picture is messier than a TikTok can capture. Head-to-head tolerability data exists, and it does not obviously favor tirzepatide across the board.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) reported nausea in roughly 30-33% of tirzepatide participants depending on dose, compared to about 14% on placebo. The STEP 1 trial for semaglutide 2.4mg (Wilding et al., 2021, NEJM) showed nausea in approximately 44% of participants. That gap is real, but context matters: doses were not equivalent, titration schedules differed, and individual variation is enormous. A 2023 retrospective analysis by Ghusn et al. in Obesity Pillars found that in real-world patients switching between GLP-1 agents, nausea patterns were highly individual and not consistently predicted by drug class.
The creator also mentioned taking ondansetron (Zofran) proactively after waking nauseous at 5 a.m. That is a clinically reasonable move, and antiemetics are sometimes recommended by prescribers to manage early GLP-1 side effects, though this should always be directed by a physician.
What did they get wrong (or right)?
They got the general direction right: some clinical and real-world data does suggest tirzepatide may produce less nausea in a subset of patients compared to semaglutide at weight-loss doses. Credit where it is due.
What they got wrong, or at least incomplete: comparing "day one" of tirzepatide to the worst stretch of semaglutide is not an apples-to-apples comparison. Most GLP-1 nausea occurs during dose escalation, typically weeks 4-12, not at initiation. The creator may be comparing their best tirzepatide day to their worst semaglutide days. That framing misleads viewers who might assume tirzepatide is simply the easier drug, full stop.
The hashtags also misspell tirzepatide twice (#trizpeitide, #trizepitide), which matters because misspelled tags can attract audiences less familiar with the medication, who may take this anecdote as clinical guidance. It is not.
- Nausea comparison may be valid directionally, but timing of comparison is flawed
- Individual response to either drug varies significantly
- Ondansetron use should always be physician-directed
What should you actually know?
If you had a rough time on semaglutide and are curious about tirzepatide, the question is legitimate. But there are real things to understand before drawing conclusions from one person's day one.
Tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide is a GLP-1 agonist only. The different receptor profile may influence tolerability for some people, but it also means they are not equivalent drugs and should not be treated as interchangeable. The SURPASS-CVOT trial and SURMOUNT program data both show tirzepatide's side effect profile is real and dose-dependent. Some patients switch from semaglutide to tirzepatide and feel worse, not better.
Nausea management strategies, such as eating smaller meals, avoiding high-fat foods, and in some cases using antiemetics under physician guidance, apply to both medications. If you are struggling with nausea on either drug, that conversation belongs with your prescriber, not a TikTok comment section.
- Both medications carry FDA warnings about potential thyroid C-cell tumors in rodents; long-term human data is still accumulating
- Neither drug is appropriate without medical supervision and proper screening
- Compounded versions of these peptides are not equivalent to the FDA-approved branded products